Many patients and parents have been taught that you must “prove” a condition with a test before you can treat it. In this talk, Dr. Patrick Nemechek explains why that assumption often breaks down in real-world medicine—especially for small intestinal bacterial overgrowth (SIBO).
He outlines what SIBO is, why it can drive body-wide inflammation, and why several popular diagnostic tools can be misleading. He then describes the approach he believes is most practical in outpatient care: using clinical judgment and an empirical treatment trial to both treat and clarify whether SIBO is present.
Educational medical disclaimer: This article summarizes Dr. Nemechek’s clinical framework from the provided transcript for general education only. It is not medical advice and does not replace individualized evaluation and treatment from a licensed clinician.
What SIBO is (and why it matters systemically)
Dr. Nemechek defines SIBO as small intestinal bacterial overgrowth—a problem of bacteria being in the wrong place. He describes a normal intestinal balance as having very few bacteria in the small intestine compared with the large intestine. In his “birds and fish” analogy, “bird” bacteria live higher up, while “fish” bacteria live in the large intestine, with a massive normal ratio difference (he describes the small intestine as “really almost sterile” in comparison).
In SIBO, Dr. Nemechek says that “fish” bacteria appear in the small intestine, where they don’t belong. In his model, this can “overwhelm” the small intestine and “breach the barrier,” leading to increased intestinal permeability (often called “leaky gut”). He links this to a “massive release of inflammatory stress throughout the body,” potentially affecting many organ systems.
He highlights LPS (lipopolysaccharide) as a highly inflammatory molecule associated with “fish” bacteria. He also notes that, in his discussion of children with autism, he suspects certain bacteria may be producing propionic acid, which he describes as having an effect “kind of a combination of a sedative and LSD,” and he suggests this could help explain some unusual behaviors when children are young. These points reflect his clinical interpretation as presented in the transcript.
Testing options: what’s “gold standard,” and what isn’t
1) Small intestinal aspirate culture (gold standard—mostly for research)
For research settings, Dr. Nemechek describes the gold-standard method as a jejunal aspirate culture. In this procedure, a long scope is used while the patient is unconscious, and fluid is collected from the small intestine for bacterial quantification.
He emphasizes several limitations that make it a poor fit for routine outpatient diagnosis, especially in children:
- Invasive and expensive
- Difficult to perform accurately (requires estimating bacterial concentration)
- Contamination risk as the scope passes through the mouth (requiring special procedures)
- Sampling limitations (it may only reflect the upper small intestine, while overgrowth could be lower down)
Because of those issues, he frames aspirate culture as primarily a research tool rather than a practical repeatable test for monitoring response to treatment in everyday clinical care.
2) Breath testing (common—but frequently wrong in his view)
Breath tests typically involve giving a sugar substrate (Dr. Nemechek mentions glucose or lactulose). If overgrown bacteria are present, they ferment the sugar and produce gases such as hydrogen or methane, which are measured over time.
However, Dr. Nemechek argues that breath tests have a high rate of false positives and false negatives. In the transcript, he states some studies suggest results may be wrong 30–40% of the time. From his perspective, that level of inaccuracy makes the test unhelpful for guiding clinical decisions, and he says it can actively prevent patients from getting treated when symptoms strongly suggest SIBO but the breath test is “negative.”
What Dr. Nemechek recommends instead: an empirical (symptom-based) trial
Dr. Nemechek’s preferred outpatient approach is an empirical treatment trial. “Empirical,” as he explains it, means a physician uses symptoms and clinical pattern recognition to select a reasonable therapy and then observes whether the patient improves—similar to how clinicians often handle likely sinus infections without requiring imaging.
In his framework, this approach is especially useful because the treatments he mentions are specific: he states that inulin (which he says is best in little kids) and rifaximin (which he suggests for late teens and adults) can only help by addressing the problem of “fish bacteria” being present in the small intestine. If the patient improves, he considers that improvement highly suggestive that SIBO was the driver.
He also emphasizes safety considerations in his discussion: he describes rifaximin as “very, very safe,” and he states there is not known to be a risk for antibiotic resistance with rifaximin. He further states it is the only antibiotic that does not damage the biome, contrasting it with antibiotics like azithromycin (“Z-pack”) or ciprofloxacin, which he says can permanently damage the gut biome. (These points reflect his claims as stated in the transcript.)
Tests Dr. Nemechek says do not diagnose SIBO
Stool tests
Dr. Nemechek is direct that stool testing cannot diagnose SIBO. His reasoning is anatomical: stool collected from the rectum reflects the large intestine and does not provide information about what is happening in the small intestine. He cautions patients not to be persuaded by attractive charts or scientific-sounding interpretations if the question is specifically whether bacteria are overgrowing in the small intestine.
Blood tests
He also rejects the idea that a blood test can determine whether someone has SIBO, stating there is “no such thing” as a blood test that can reliably do that.
How to use this information in a clinical conversation
Dr. Nemechek’s message is that clinicians should not be forced into relying on tests that may misdirect care. In his view, if symptoms and history are suggestive of SIBO, the most useful next step in routine practice is often a carefully chosen empirical trial—because it can both start treatment promptly and function as a practical diagnostic confirmation when symptoms improve.
If you are considering evaluation for SIBO, discuss risks, benefits, and appropriateness of different diagnostic strategies with your clinician—especially if a negative breath test is being used to block treatment despite a symptom pattern that strongly suggests SIBO.
